Gilead Stock Hits New 52-Week High (GILD)

NEW YORK ( TheStreet) -- Gilead (Nasdaq: GILD) hit a new 52-week high Friday as it is currently trading at $74.14, above its previous 52-week high of $73.20 with 2.6 million shares traded as of 9:50 a.m. ET. Average volume has been 8.2 million shares over the past 30 days.

Gilead has a market cap of $108.99 billion and is part of the health care sector and drugs industry. Shares are up 93.5% year to date as of the close of trading on Thursday.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. The company has a P/E ratio of 39.1, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Gilead Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition